A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 30 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 30 May 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.
- 29 Mar 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.